Drug Royalty is a pioneer in pharmaceutical royalty monetization, building a diversified portfolio of interests in medicines that effectively treat and address unmet medical needs. With over 0 years of experience and a track record of acquiring dependable, patent-protected cash flow streams from the sales of important drugs across multiple therapeutic areas, they are a trusted partner for investors and innovators alike. As a smart capital allocator, Drug Royalty actively sources royalty streams on medically necessary products with long-term patent protection and high growth potential, driving value creation for their portfolio. They provide uniquely favorable exposure for investors through a risk-mitigated portfolio of therapeutic assets, aiming to generate attractive returns and significant growth potential.Generated from the website